Beone Medicines Ltd (ONC) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Beone Medicines Ltd   (NASDAQ: ONC)


Beone Medicines Ltd 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Beone Medicines Ltd 's ROA in the second quarter of 2026?
Beone Medicines Ltd achieved a return on average assets (ROA) of 7.8 % in its second quarter of 2026, this is above ONC's average return on assets of -24.23%.
Beone Medicines Ltd s assets during the 12 months ending in the second quarter of 2026 are valued at $8 billion

ROA has improved compared to 6.73% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 120 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 935, from total ROA ranking in the first quarter of 2026 at 1580.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 51.02 % 50.09 % 42.97 % 30.68 % 9.92 %
Y / Y Net Income Change 151.28 % 17802.13 % - - -
Net Income (TTM) in million 656 513 287 69 -178
Return On Assets (TTM) 7.8 % 6.73 % 4.15 % 1.09 % -3.04 %
ONC's Total Ranking # 935 # 1580 # 2162 # 2895 # 3181
Total Assets (TTM) in million 9,317 8,554 8,267 7,493 6,169
Seq. Total Assets Change 8.92 % 3.47 % 10.33 % 21.46 % 8.25 %
Seq. Net Income Change 4.24 % 241.88 % -46.73 % 32.36 % 7326.77 %

ONC's 5 Years Annual ROA >> Back to ONC Management Effectiveness >> Compare ONC ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 46
Sector # 121
Overall # 787

Return On Assets Statistics
High Average Low
7.82 %
-24.23 %
-61.32 %
  (Jun 30 2017)





Financial Statements
Beone Medicines Ltd 's Assets $ 9,317 million ONC's Balance sheet
Beone Medicines Ltd 's Income $ 237 million Quarterly ONC's Income Statement
ONC's Income by Division See ONC's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 41.62 % 1.25 % -8.95 % -25.52 % 54.6 %
Total Assets in million 8,189 5,782 5,711 6,272 8,421
Y / Y Net Income Change - - - - -
Net Income in million 287 -645 -882 -2,004 -1,413
Annual Return On Assets 3.5 % -11.15 % -15.44 % -31.95 % -16.78 %

ONC's 5 Years Annual ROA >> Back to ONC Management Effectiveness >> Compare ONC ROA to its Competitors



Comment on ONC's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 3.5 % compared to prior year, due to annual net income growth of % to $286.93 million, while value of Beone Medicines Ltd 's overall assets grew just by 41.62 % to $8,188.57 million, compared to $8,188.57 a year before.


More Return On Assets Ratios
ONC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ONC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ONC's Competitors
Subscribers only: Roa for Beone Medicines Ltd 's Suppliers
Subscribers only: Return On Assets for ONC's Customers

You may also want to know
ONC's Roi ONC's Inventory Turnover Ratio ONC's Growth Rates ONC's Dividend Comparisons
ONC's Profitability Ratios ONC's Asset Turnover Ratio ONC's Dividend Growth
ONC's Roe ONC's Valuation Ratios ONC's Financial Strength Ratios ONC's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %
Standard Biotools Inc   14.31 %
Arcutis Biotherapeutics Inc   14.23 %
Harmony Biosciences Holdings inc   14.15 %
Biolife Solutions Inc   14.09 %
Aveanna Healthcare Holdings Inc   13.82 %
West Pharmaceutical Services Inc   13.64 %
Medinotec Inc   13.38 %
Puma Biotechnology Inc   13.28 %
Sbc Medical Group Holdings Incorporated  13.26 %
Alpha Pro Tech Ltd   13.17 %

Date modified: 2026-09-11T09:58:09+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.